Ib Christian Klausen

Ib Christian Klausen

Auto-generated profile, based on publicly available information

Ib Christian Klausen

The Danish FH Study Group , Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2018 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
MDMarie Dahl
Marie Dahl
LFLars Frost
Lars Frost
RSRikke Søgaard
Rikke Søgaard
IKIb Christian Klausen
Ib Christian Klausen
VLVibeke Lorentzen
Vibeke Lorentzen
JLJes Sanddal Lindholt
Jes Sanddal Lindholt
Reducing women’s cardiovascular risk and the economic costs associated with cardiovascular diseases (CVD) and diabetes (DM) continues to be a challenge. Whether a multifaceted CVD screening programme is beneficial as a preventive strategy in women remains uncertain. The aim of this study was to investigate the prevalence of CVD and DM as well as the acceptability toward screening and preventive actions. An observational study was performed among all women born in 1936, 1941, 1946 and 1951 living in Viborg Municipality, Denmark, from October 2011. In total, 1984 were invited to screening for abdominal aortic aneurysm (AAA), peripheral arterial disease (PAD), carotid plaque (CP), hypertension (HT), atrial fibrillation (AF), DM and dyslipidaemia. Participants with positive tests were offered prophylactic intervention including follow-up consultations in case of AAA, PAD and/or CP. Participants with AAA ≥ 50 mm were referred to specialists in vascular surgery. Women with AF or potential familial hypercholesterolaemia (FH) were referred to cardiology work-up. Among those invited, 1474 (74.3%) attended screening, but the attendees’ share decreased with increasing age groups (p < 0.001). AAA was diagnosed in 10 (0.7%) women, PAD in 101 (6.9%) and CP in 602 (40.8%). The percentage of women with these conditions rose with increasing age group (p < 0.05). Unconfirmed potential HT was observed in 94 (6.4%), unknown AF in 6 (0.4%), DM in 14 (1%) and potential FH in 35 (2.4%). None of these findings differed across age groups. Among the 631 women diagnosed with AAA, PAD and/or CP, 182 (28.8%) were already in antiplatelet and 223 (35.3%) in lipid-lowering therapy prior to screening. Antiplatelet therapy was initiated in 215 (34.1%) and lipid-lowering therapy in 191 (30.3%) women. Initiation of antiplatelet and lipid-lowering therapy was further recommended to 134 (21.2%) and 141 (22.4%) women, respectively, who hesitated to follow the recommendation. The study recorded an acceptable total attendance rate, even though a significantly lower attendance rate was observed in the eldest women. The identified hesitation towards prophylactic therapy may affect the rationale and effectiveness of CVD screening, and hesitation seems a critical issue that should be addressed in the design of future screening programmes.

20 October 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
BHBerit Storgaard Hedegaard
Berit Storgaard Hedegaard
BNBørge Grønne Nordestgaard
Børge Grønne Nordestgaard
HKHelle Lynge Kanstrup
Helle Lynge Kanstrup
KTKristian Korsgaard Thomsen
Kristian Korsgaard Thomsen
JBJan Bech
Jan Bech
CBChristian Bork
Christian Bork
Background Cholesterol carried in lipoprotein(a) adds to measured low-density lipoprotein cholesterol (LDL-C) and may therefore drive some diagnoses of clinical familial hypercholesterolemia (FH). We investigated plasma lipoprotein(a) in subjects referred to Danish lipid clinics and evaluated the impact of plasma lipoprotein(a) for a diagnosis of FH. Methods Individuals referred to 15 Danish lipid clinics suspected of FH according to nationwide referral criteria were recruited between September 1st 2020 and November 30th 2021. All individuals were classified according to the Dutch Lipid Network criteria for FH before and after LDL-C was adjusted for 30% cholesterol content in lipoprotein(a). We calculated the fraction of individuals fulfilling a clinical diagnosis of FH partly due to elevated lipoprotein(a). Results We included a total of 1,166 individuals for analysis, of whom 206 fulfilled a clinical diagnosis of FH. Median lipoprotein(a) was 15 mg/dL (29 nmol/L) in those referred and 28% had lipoprotein(a) ≥50 mg/dL (105 nmol/L), while 2% had levels ≥180 mg/dL (389 nmol/L). We found that 27% (55/206) of those fulfilling a clinical diagnosis of FH was partly due to high lipoprotein(a). Conclusions Elevated lipoprotein(a) was common in individuals referred to Danish lipid clinics and one quarter of individuals who fulfilled a clinical diagnosis of FH were partly due to elevated lipoprotein(a). These findings support the notion that the LPA gene should be considered an important causative gene in patients with clinical FH and further support the importance of measuring lipoprotein(a) when diagnosing FH as well as for stratification of cardiovascular risk.

1 January 2021 in Atherosclerosis
Verified
Journal Article
Open access
KSKarianne Svendsen
Karianne Svendsen
GLGisle Langslet
Gisle Langslet
HKHenriette W. Krogh
Henriette W. Krogh
JBJonas Brinck
Jonas Brinck
IKIb Christian Klausen
Ib Christian Klausen
KRKjetil Retterstøl
Kjetil Retterstøl
In familial hypercholesterolemia (FH), statin treatment should be considered from 8 to 10 years of age, but the prevalence of statin use among children is not known. Statin use (2008-2018) among children aged 10-14 and 15-19 years was obtained from the national prescription databases in Norway, Sweden and Denmark. We assumed that all statin users in these age groups had FH, and that the estimated prevalence of FH is 1 in 250 inhabitants. Changes in prevalence rates of statin use between 2008 and 2018 by country, age and sex were estimated using the Joinpoint Regression Program version 4.8.0.1. Differences in prevalence rate ratio each year between countries were analyzed using Poisson regression. Among children aged 10-14 years, there was a significant increase in statin use in Norway and Denmark between 2008 and 2018, while in Sweden an increase was only seen after 2014. Among children aged 15-19 years, an increase in statin use was only observed in Norway and Sweden between 2008 and 2018. Statin use was significantly more prevalent in Norway than in Sweden and Denmark each year, and in 2018 the proportion of children using statins was 4-5 times (10-14 years) and 3 times (15-19 years) higher in Norway compared with Sweden and Denmark. In 2018 in Norway, 19% and 35% of children aged 10-14 years and 15-19 years estimated to have FH used statins respectively; corresponding percentages in Sweden were 4.5% and 10%, and in Denmark 3% and 12%. In Norway, the increase in statin use between 2008 and 2018 roughly corresponded to the increase in children with genetically verified FH. Between 2008 and 2018, statin use increased in children aged 10-19 years in Norway, Sweden and Denmark, but with large differences between the countries; statin use was 3-5 times more prevalent in Norway than in Sweden and Denmark, which may be due to a more widespread use of genetic testing for FH in Norway.